GT Biopharma, Inc. financial data

Symbol
GTBP on Nasdaq
Location
San Francisco, CA
Fiscal year end
31 December
Latest financial report
02 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 232% % 45%
Debt-to-equity 69% % 49%
Return On Assets -174% % -293%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31,553,892 shares 1312%
Common Stock, Shares, Outstanding 25,534,173 shares 1043%
Entity Public Float $8,600,000 USD 69%
Common Stock, Value, Issued $26,000 USD 1200%
Weighted Average Number of Shares Outstanding, Basic 5,513,255 shares 191%
Weighted Average Number of Shares Outstanding, Diluted 5,513,255 shares 191%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $3,472,000 USD -40%
Operating Income (Loss) $12,422,000 USD 14%
Nonoperating Income (Expense) $15,932,000 USD -1425%
Net Income (Loss) Attributable to Parent $28,354,000 USD -115%
Earnings Per Share, Basic -6.68 USD/shares 3.7%
Earnings Per Share, Diluted -6.68 USD/shares 3.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $6,811,000 USD 72%
Cash, Cash Equivalents, and Short-term Investments $9,200,000 USD -49%
Assets, Current $8,106,000 USD 92%
Operating Lease, Right-of-Use Asset $27,000 USD -81%
Assets $8,106,000 USD 92%
Accounts Payable, Current $748,000 USD -81%
Accrued Liabilities, Current $1,560,000 USD -13%
Liabilities, Current $2,319,000 USD -61%
Liabilities $1,321,000 USD
Retained Earnings (Accumulated Deficit) $723,901,000 USD -4.1%
Stockholders' Equity Attributable to Parent $5,787,000 USD
Liabilities and Equity $8,106,000 USD 92%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,202,000 USD 47%
Net Cash Provided by (Used in) Financing Activities $616,000 USD
Net Cash Provided by (Used in) Investing Activities $5,034 USD
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 25,534,173 shares 1043%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,586,000 USD -282%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6,905,000 USD 71%
Deferred Tax Assets, Valuation Allowance $141,106,000 USD 26%
Deferred Tax Assets, Gross $141,106,000 USD 26%
Operating Lease, Liability $30,000 USD -81%
Lessee, Operating Lease, Liability, to be Paid $30,000 USD -80%
Operating Lease, Liability, Current $30,000 USD -74%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $0 USD -100%
Preferred Stock, Shares Authorized 15,000,000 shares 0%
Additional Paid in Capital $729,661,000 USD 5.2%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%